Author:
Sanchez-Piedra Carlos,Hernández Miguel M. Victoria,Manero Javier,Roselló Rosa,Sánchez-Costa Jesús Tomás,Rodríguez-Lozano Carlos,Campos Cristina,Cuende Eduardo,Fernández-Lopez Jesús Carlos,Bustabad Sagrario,Martín Domenech Raquel,Pérez-Pampín Eva,del Pino-Montes Javier,Millan-Arciniegas Ana Milena,Díaz-González Federico,Gómez-Reino Juan Jesús
Funder
Spanish Agency of Medicines and Healthcare Products
Reference29 articles.
1. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases;Gabriel;Arthritis Res Ther,2009
2. Prevalencia e impacto de las enfermedades reumáticas en la población adulta española;Episer,2001
3. Annual report. Spanish Registry on adverse events of biological therapies in rheumatic diseases;Rheumatology SCoBRUSSo,2015
4. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness;Chen;Health Technol Assess,2006
5. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial;Inman;Arthritis Rheum,2008